[18F]FET PET Imaging for Early Response Assessment of Bevacizumab in Recurrent Glioblastoma
Clicks: 1
ID: 325093
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #98 of 103 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Bevacizumab combination therapy has shown response in approximately 25% of recurrent Glioblastoma (GBM) patients. This study aimed to investigate the value of O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography ([18F]FET PET) imaging and the relevance of the PET-based response assessment criteria for diffuse gliomas (PET RANO) criteria in assessing response to bevacizumab combination therapy in recurrent GBM. Material and methods All recurrent GBM IDH-wildtype patients treated with bevacizumab plus irinotecan at Rigshospitalet (year 2018-2022) and evaluated with consecutive [18F]FET PET imaging at baseline and after 2 cycles of treatment were included. Metabolic tumour volumes (MTV), maximum tumour-to-background ratios (TBRmax), mean tumour-to-background ratios (TBRmean) and associated changes were determined. Cox regression and receiver operating characteristic analyses were used to identify predictors of survival beyond the median overall survival (OS). Results 82 patients (median OS 9.3 months, 95% Confidence interval: 8.3–10.4) were included. Tumours were smaller and less metabolically active at follow-up. PET RANO showed a 68% response rate and was independently associated with a longer OS (p < 0.001). Analysis of individual PET parameters identified three thresholds that independently predicted longer OS with response rates of 35–40%: i) more than 76% reduction in MTV, ii) more than 21% reduction in TBRmax iii) follow-up MTV under 3.5 cm3. Conclusion On using [18F]FET PET for response assessment during bevacizumab treatment, the proposed response criteria improved identification of responders when compared with the PET RANO criteria. Nevertheless, further refinement and validation is needed to enhance PET-based response assessment.
| Reference Key |
openalex_W7203616616
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Shivani Chiranth, O. Henriksen, Benedikte Hasselbalch, Kirsten Grunnet, Jonathan Frederik Carlsen, Hans Skovgaard Poulsen, Ian Law, Karine Madsen, Thomas Urup |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag213
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.